<DOC>
	<DOC>NCT01950364</DOC>
	<brief_summary>This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.</brief_summary>
	<brief_title>A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Male or female participants between 18 years and 75 years old, with relapsed or refractory HL or relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy Measurable disease An Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1 Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence Clinical laboratory values as specified in the study protocol Participants for whom rifampicin is contraindicated Previously received an allogeneic transplant. Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma (ALCL) (participants whose ALCL has transformed to sALCL are eligible). Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML) Female participants who are lactating and breastfeeding or pregnant Known human immunodeficiency virus (HIV) positive, Known hepatitis B surface antigenpositive, or known or suspected active hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin</keyword>
	<keyword>Anaplastic Large-cell</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>